Clinical Trial Protocol

A clinical trial protocol is the formal document that defines a clinical trial’s objectives, design, methodology, statistical considerations, and organization. It is the single controlling reference for how a study is conducted: it tells investigators what to do, tells the Institutional Review Board/independent ethics committee (IRB/IEC) what to review and approve, and tells sponsors and monitors what to check compliance against. Every other study document — the informed consent form, case report forms, the statistical analysis plan, monitoring plans — is written to be consistent with the protocol, not the other way around.

What the protocol has to contain

The current core Good Clinical Practice guideline, ICH E6(R3) (finalized/adopted 6 January 2025, with EMA setting 23 July 2025 as the EU effective date for the Principles and Annex 1, and FDA issuing its own final E6(R3) guidance on 8 September 2025), sets out the elements a protocol needs to address. In substance — consistent with the structure carried forward from ICH E6(R2) — a protocol needs to cover:

• Background and rationale — the scientific justification for the trial and summary of relevant nonclinical/clinical findings, typically cross-referencing the Investigator’s Brochure rather than repeating it.
• Objectives and endpoints — primary and secondary objectives, and the specific endpoints used to measure them.
• Trial design — the type of study (e.g. randomized, blinded, parallel-group, crossover), the interventions being compared, and the overall schema.
• Selection and withdrawal of subjects — inclusion/exclusion criteria and the procedures and reasons for withdrawing a participant.
• Treatment of subjects — the investigational product(s), dosing, permitted/prohibited concomitant therapy.
• Assessment of efficacy and safety — what is measured, how, and on what schedule, including adverse event definitions and reporting procedures.
• Statistics — the planned statistical methods, sample size justification, and significance level; this section is elaborated in full in the separate Statistical Analysis Plan (see below).
• Data governance and quality management — ICH E6(R3) gives this materially more explicit emphasis than prior revisions, reflecting its broader shift toward risk-based, proportionate quality management across the trial lifecycle.
• Ethics — a description of ethical considerations relating to the trial, and confirmation the trial will be conducted in accordance with the protocol, GCP, and applicable regulatory requirements.
• Administrative provisions — data handling and record-keeping, publication policy, financing and insurance, as applicable.

Large multi-site or complex trials commonly separate out a shorter protocol synopsis for quick reference, and may issue a companion Statistical Analysis Plan (SAP) as a distinct document rather than folding every analytical detail into the protocol body — see below.

Protocol amendments and deviations

Once a protocol is approved, changes to it are controlled, not informal. A protocol amendment is a written description of a change to, or formal clarification of, the protocol. Amendments that could affect participant safety, the scope of the investigation, or the scientific quality of the trial (a substantial amendment) require review and approval by the IRB/IEC — and, depending on jurisdiction and the nature of the change, notification to or approval from the regulatory authority — before the change takes effect. Amendments that meaningfully change what a participant is asked to do, or their risk exposure, typically also require re-consent of already-enrolled participants.

A protocol deviation is different: it is an instance of conduct that departs from the approved protocol without prior IRB/sponsor approval, whether inadvertent or, in a genuine emergency, taken to protect a participant’s immediate safety. Deviations are tracked, reported per the site’s and sponsor’s procedures, and reviewed for whether they indicate a need for retraining, a corrective action plan, or a protocol amendment.

Relationship to the Statistical Analysis Plan (SAP)

The protocol’s statistics section states the planned analysis approach at a level sufficient for ethics and regulatory review; the Statistical Analysis Plan is typically a separate, more granular document that finalizes the exact statistical methodology — specific models, handling of missing data, definitions of analysis populations (e.g. intention-to-treat vs. per-protocol analysis), and the full set of planned tables/figures — before the trial is unblinded. Finalizing and locking the SAP ahead of database lock and unblinding is standard practice specifically to prevent the analysis being shaped by knowledge of the results.

Relationship to IRB/ethics review

The protocol is the primary document an IRB or independent ethics committee reviews and must approve before a trial can enroll participants at a given site, and re-review whenever a substantial amendment is proposed. IRB review of the protocol assesses, among other things, whether risks to participants are minimized and reasonable relative to anticipated benefits, whether the selection of subjects is equitable, and whether informed consent will be sought and documented appropriately — all judged against what the protocol actually specifies.

Related terms

• ICH E6(R3) — the current core GCP guideline the protocol’s required content derives from.
• ICH GCP (Good Clinical Practice)
• Clinical Study
• Intent-to-Treat (ITT) vs. Per-Protocol Analysis
• Clinical Trial Phases
• Informed Consent in Research